Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)

Subscribe to Selected New Research on Diphtheria-Tetanus-acellular Pertussis Vaccines

147 relevant articles (11 outcomes, 35 trials/studies) found for this Bio-Agent

Description: Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.

Also Known As:

Tripedia; ACEL-IMUNE; DTaP Vaccine; Infanrix; ACEL IMUNE; ACELIMUNE; Diphtheria Tetanus acellular Pertussis Vaccines; Pertussis Vaccines, Diphtheria-Tetanus-acellular; Vaccine, DTaP; Vaccines, DTaP; Vaccines, Diphtheria-Tetanus-acellular Pertussis; DTaP Vaccines

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kataoka, M: 2 articles (10/2001 - 03/2001)
2.	Horiuchi, Y: 2 articles (10/2001 - 03/2001)
3.	Ochiai, M: 2 articles (10/2001 - 03/2001)
4.	Toyoizumi, H: 2 articles (10/2001 - 03/2001)
5.	Yamamoto, A: 2 articles (10/2001 - 03/2001)
6.	Dickinson, Robert: 1 article (04/2006)
7.	Corbel, Michael J: 1 article (04/2006)
8.	Sesardic, Dorothea: 1 article (04/2006)
9.	Xing, Dorothy K L: 1 article (04/2006)
10.	Douglas-Bardsley, Alexandra: 1 article (04/2006)

Related Diseases

1.	Whooping Cough (Pertussis) 08/01/2005 - "CONCLUSIONS: Any combination of > or =3 DTP/DTaP vaccine doses for children 6 to 59 months of age was highly protective against pertussis. " 05/01/2009 - "Pertussis and the DTaP Vaccine." 08/01/2008 - "In fully immunised children, receipt of all three doses of the primary course as an acellular pertussis-containing combination vaccine (DTaP-Hib) increased the risk of vaccine failure (OR 2.88 (95% CI 0.99 to 8.37), p = 0.01). " 08/01/2005 - "The proportions of children who received 0, 1 or 2, 3, and > or =4 pertussis (DTP and/or DTaP) vaccine doses among case subjects were 26%, 14%, 26%, and 34% and among control subjects were 2%, 8%, 33%, and 57%, respectively. " 01/01/2005 - "The economic impact of pertussis and transmission from adults to vulnerable infants provides a cost-benefit justification for widespread use of DTaP vaccines in all age groups with routine boosting every 10 years." Order ALL the reference details at left...
2.	Diphtheria 03/01/2009 - "More recently, a refinement of this method based on dermal temperature measurement has been developed for ACVs in combination with diphtheria and tetanus vaccines (DTaP). " 05/09/2005 - "Significantly (p < or =0.0001) higher antibody levels against diphtheria and the 3 polio components were also induced by Infanrix hexa. " 01/01/1996 - "Tetanus antibody was higher pre- and post-vaccination for DTwP versus both DTaP vaccine groups, and diphtheria antibody was similar pre- and post-vaccination for all 3 groups. " 01/01/2005 - "Replacement of the diphtheria and aP components with these improved antigens will reduce the amount of protein in DTaP vaccine and, most likely, the incidence and severity of local reactions in teenagers and adults." 10/01/2007 - "The diphtheria-tetanus-acellular pertussis (DTaP) vaccine was considered in the analysis. " Order ALL the reference details at left...
3.	Tetanus 03/01/2009 - "More recently, a refinement of this method based on dermal temperature measurement has been developed for ACVs in combination with diphtheria and tetanus vaccines (DTaP). " 01/01/1996 - "Tetanus antibody was higher pre- and post-vaccination for DTwP versus both DTaP vaccine groups, and diphtheria antibody was similar pre- and post-vaccination for all 3 groups. " 01/01/1996 - "These 2- and 3-component DTaP vaccines produce less common reactions and comparable or higher antibody to the components they contain (except tetanus) than DTwP vaccine when given as a booster to 15- to 20-month-old children previously primed with the same vaccine." 10/01/2007 - "The diphtheria-tetanus-acellular pertussis (DTaP) vaccine was considered in the analysis. " 09/01/2007 - "OBJECTIVE: Low childhood immunization rates have been a challenge in Colorado, an issue that was exacerbated by a diphtheria-tetanus-acellular pertussis (DTaP) vaccine shortage that began in 2001. " Order ALL the reference details at left...
4.	Infection 01/01/1998 - "In contrast with DTP, the DTaP vaccine had some efficacy against B parapertussis infection (point estimate for cough >/=7 days: 31% [95% CI: -10-56]). " 01/01/1998 - "Like other multicomponent acellular pertussis vaccines, the Lederle/Takeda DTaP vaccine demonstrated good efficacy against mild and typical pertussis due to B pertussis infections. " 06/04/1999 - "In a respiratory mouse model, a tricomponent acellular pertussis vaccine (Infanrix) was highly effective in promoting lung clearance of all isolates expressing different S1 subunit and pertactin suggesting that use of acellular vaccine will not increase the risks of pertussis infection by these B. " Order ALL the reference details at left...
5.	Cough 01/01/1998 - "For DTaP vaccine, efficacy was higher after the fourth dose as compared with its efficacy after the third dose (78% vs 62% for cough >/=7 days and 85% vs 76% for cough >/=21 days with PWV). " 10/01/1998 - "RESULTS: Using a clinical case definition that included both mild and typical pertussis (cough illness >/=7 days duration) efficacy of DTaP vaccine was 40% (95% confidence interval [CI] = -3-65) in the high compliance category and 78% (95% CI = 65-86) and 75% (95% CI = 53-87) in the intermediate and low compliance groups, respectively. " 01/01/1998 - "In contrast with DTP, the DTaP vaccine had some efficacy against B parapertussis infection (point estimate for cough >/=7 days: 31% [95% CI: -10-56]). " 10/01/1998 - "Using a clinical case definition that required >/=21 days of cough with paroxysms, whoop, or vomiting (typical pertussis) the efficacy of DTaP vaccine was 69% (95% CI = 41-83) in the high compliance category and 86% (95% CI = 76-92) and 84% (95% CI = 64-93) in the intermediate and low compliance groups, respectively. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Pertussis Vaccine
2.	Antigens
3.	pertactin
4.	Vaccines
5.	Toxoids
6.	Hemagglutinins (Hemagglutinin)
7.	pertussis toxoid
8.	Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)
9.	DNA (Deoxyribonucleic Acid)
10.	Diphtheria-Tetanus Vaccine

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Injections
3.	Day Care (Partial Hospitalization)

Best Treatments:
Research Summary Report
on Whooping Cough

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 288 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>